ARK Genomic Revolution ETF vs Barclays PLC — how do they compare? ARK Genomic Revolution ETF trades at $44.66, while Barclays PLC trades at $28.08 (market cap $93.87B). The key difference: Barclays PLC pays a 2.19% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | BCS | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $28.56 |
52-Week Low | $24.02 | $19.36 |
Market Cap | — | $93.87B |
Dividend Yield | — | 2.19% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Barclays PLC (BCS) trades at $27.98, up 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals, including a P/E of 10.68, P/B of 0.88, and net income margin of 25.51%, with Q2 2026 EPS beating estimates at $0.90. Recent news highlights a 17% profit jump in H1 2026 but also a securities class action investigation, creating mixed sentiment.
The outlook is cautiously optimistic, supported by earnings beats and a 68% analyst buy rating, but risks include cost pressures, legal scrutiny, and market volatility. Upside potential hinges on sustained profit growth and efficient cost management amid economic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →